TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02135926

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical care
Description: Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
Study: NCT00828204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-use autoinjector with a prefilled liquid Avonex syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avonex prefilled syringe via manual IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (interferon beta-1a)
Study: NCT02863120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study: NCT04239014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match olaparib
Description: Per olaparib
Study: NCT02373683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm-Heliox
Description: Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
Study: NCT04960657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP38
Description: PACAP38 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP38
Description: PACAP38 infusion
Study: NCT01568242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemlsification
Description: Transurgical measurement of temperature
Study: NCT02753452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential Immersive Life Skills programming

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-residential life skills programming
Study: NCT00590265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Northern Light Technology (SADelite lamp) bright light-therapy
Description: 10 000 lux for 30 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Northern Light Technology (SADelite lamp) Dim light-therapy
Description: \<100 lux for 30 minutes
Study: NCT01642589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular
Study: NCT02758184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM-based coagulation monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spine surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Study: NCT00619710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem-cilastatin
Description: Intravenous
Study: NCT03752567

Intervention type: OTHER
Intervention: Follow up
Description: like group descriptions
Study: NCT02606513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Urography; CT Urography
Study: NCT02390193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study.
Study: NCT03172988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study: NCT04545580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be taken twice daily orally as tablet(s)
Study: NCT04440904

Intervention type: DEVICE
Intervention: CT workstation (Syngo Via VB10B, Siemens, Germany)
Description: Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
Study: NCT02668978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch™ Sealing Hemostat
Description: Hemopatch™ application over lung resection areas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical technique
Description: Lung resuturing or restapling
Study: NCT01815697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation
Description: Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
Study: NCT01287741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Study: NCT04421027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03071419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Parenting Intervention
Description: The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Parenting Intervention
Description: The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
Study: NCT02581241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tilt table
Description: Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tilt table
Description: Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital
Study: NCT02608684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV solution
Study: NCT03531112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Awareness Treatment + Lifestyle Modification
Description: The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
Study: NCT02911168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Intercostal Block
Description: After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
Study: NCT04093102

Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers
Description: bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.

Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers
Description: bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
Study: NCT00890123

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven-IV FO
Description: Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
Study: NCT02044640

Intervention type: PROCEDURE
Intervention: Appendectomy
Study: NCT01987453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert.
Study: NCT03598686

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OraQuick
Description: Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
Study: NCT00880243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA
Study: NCT02824653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
Study: NCT03485378

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
Study: NCT00809718

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir and rifapentine
Description: Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days
Study: NCT02018718

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT02853617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 1
Description: Cohort 1 will receive 15 µg to be given as an IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 2
Description: Cohort 2 will receive 30 µg to be given as an IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 3
Description: Cohort 3 will receive 75 µg to be given as an IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 4
Description: Cohort 4 will receive 150 µg to be given as an IM injection
Study: NCT01597596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alglucosidase alfa
Description: IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
Study: NCT01744106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine hydrochloride 30 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT04371159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velieve U.S.
Description: The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
Study: NCT03714958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.